LUNG: the cash flow

MyFinsight

For the year ending 2025-12-31, LUNG had -$1,153K decrease in cash & cash equivalents over the period. -$32,828K in free cash flow.

Cash Flow	2025-12-31
Net loss	-54,003
Stock-based compensation expense	21,233
Impairment of capitalized software development costs	0
Change in allowance for credit losses	0
Inventory write-down (recovery), net	143
Depreciation and amortization expense	1,054
Amortization of debt discount and debt issuance costs	53
Net accretion of discounts on marketable securities	379
Non-cash lease expense	1,448
Accounts receivable	-1,075
Inventory	765
Prepaid expenses and other current assets	-813
Other assets	142
Accounts payable	270
Accrued liabilities	-2,279
Income taxes payable	194
Lease liabilities	-955
Deferred tax liability	15
Deferred revenue	-121
Net cash used in operating activities	-32,376
Purchases of investments	5,651
Maturities of investments	36,585
Purchases of property and equipment	452
Net cash provided by investing activities	30,482
Repayment of credit agreement	100
Debt issuance cost	70
Proceeds from exercise of common stock options	249
Proceeds from issuance of common stock under the employee stock purchase plan	754
Net cash provided by financing activities	833
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	-92
Net decrease in cash, cash equivalents, and restricted cash	-1,153
Cash, cash equivalents, and restricted cash at beginning of year	71,162
Cash, cash equivalents, and restricted cash at end of year	70,009

Unit: Thousand (K) dollars (except for numbers of shares and EPS).